Celebrate This High-Profit Milestone with Some More Triple-Digit Gains

This was the very first stock we recommended on the very first day Private Briefing was published – Aug. 11, 2011.

On that day, you could've owned it for less than nine bucks a share – $8.60.

That's a distant memory.

We've re-recommended these shares more than a dozen times since then, so successive "classes" of our readers can participate in these gains.

And sure enough, this stock hit an all-time high at midday yesterday… up a whopping 717% from that first day we wrote about it.

Let me tell you the ticker - and why I think there's a lot more profit in store for this "classic" pick...


The Best Biotech ETF to Buy Now Before 2017

The biotech sector is up nearly 16% over the last three months, handily beating the overall market's returns.

And the biotech sector will continue to stand out this year.

And we've got the best biotech ETF to buy before 2017...


The Way to Profit from the Biotech Story No One Is Talking About

The biotech sector has rebounded from its sharp sell-off, up 16% since June 27.

And as the comeback continues, this is the best investment to partake in the gains...


One of the Best Investments Today in the $1 Trillion IoT Market

The IoT is the growing network of objects that can be connected to Internet and the communications that occur between the two.

It's an exciting space for individuals and a lucrative one for investors. In fact, the market is already worth roughly $1 trillion.

That's why we're sharing one of the best investments today in the space....


One of the Best Biotech Stocks to Buy Now in This Booming $25 Billion Industry

When looking for the best biotech stocks to buy today, we've been targeting a brand-new subsector of the industry that is about to become a $25 billion market.

The company we're recommending today is global drug giant that has inked a partnership with a tech titan.

Keep reading for more...


These Shifting Currents Could Move Dollars Your Way

The shifting currents in bioelectronics – a $25 billion market growing 10% per year – could move dollars your way.

Consider this sector leader. Up 12% since March, it's outperforming the S&P 500...


One of the Best Biotech Stocks to Buy Could Return 52% in One Year

The biotech sector is up more than 20% recently, making now a great time to invest.

That's why Money Morning Director of Tech & Venture Capital Michael A. Robinson just recommended one of the best biotech stocks to buy.

Here's more on this investment, which could return more than 50% in the next year...


Three Tips for Investing in Biotech Stocks

The following three tips let you get the biggest profits ever when investing in biotech stocks – if you do proper research and exercise discipline.

Use these to increase your chances of getting huge biotech gains in 2016.

Continue on to biotech stock tips here...


As Gene Therapies Disrupt Big Pharma, Here's How to Get Your Piece of the Action

Gene therapy is poised to disrupt the Big Pharma industry and establish a $240 billion market.

This backdoor play - up 25% since February - is the best way to cash in...


Valeant Stock Price Rallies Today, but We're Not Buying

The Valeant stock price is up 2% today, one day after a 13% jump on Wednesday. The jump occurred after Walgreens Boots Alliance Inc. (Nasdaq: WBA) said it is pleased with its Valeant relationship.

We remain bearish on the Valeant stock price and we're not buying into the rally.

Here's why...